The Amaryllidaceae alkaloids: an untapped source of acetylcholinesterase inhibitors

The AChE inhibitory activity of alkaloid extracts and compounds has been in the focus research on plants Amaryllidoideae subfamily since approval galanthamine 2001 by FDA for treatment mild to moderate Alzheimer's disease. A small fraction huge biodiversity producing Amaryllidaceae alkaloids studied as a source inhibitors. Less than 20% known have tested vitro their ability inhibit AChE. Galanthamine, lycorine haemanthamine are scaffolds semi-synthesis potent In last years, silico drug optimization synthesis dual-binding studies other also provoked interest researchers years. aim this article is provide comprehensive review from covering literature two decades.